MAPT and Alzheimer disease: Although our focus was on establishing which biomarkers best predicted longitudinal change in the pre- and early symptomatic stages of AD, there remains interest in the testing of anti-tau compounds in patients with mild dementia due to AD.74 In addition, we cannot exclude that Aβ, tau, and neurodegeneration biomarkers or model types, including those incorporating nonlinear relationships and interactions between biomarkers, other than those investigated here may have resulted in better model fits.